Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay

Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay

Paris, France, January 24, 2018 – Sebia, a world leader in multiple myeloma diagnostics testing and monitoring, announces today that…